APG101

08/01/2015 - "APG101 has shown clinical efficacy in a controlled randomized phase II trial in patients with recurrent glioma. "
01/01/2018 - "APG101 inhibits CD95L-mediated invasion of glioma cells. "
05/01/2012 - "After the application of multiple doses of 400 mg in two glioma patients, steady state for APG101 seemed to be reached. "
05/01/2012 - "Two patients suffering from malignant glioma received APG101 intravenously under compassionate use conditions. "
01/01/2018 - "APG101 action was examined by in vitro proliferation, apoptosis, and invasion assays with human and murine glioma and human microglial cells, as well as in vivo therapy studies with orthotopic gliomas and clinical data. "

01/17/2013 - "APG101 did not interfere with the GVT effect, because P815 mastocytoma and most importantly primary Bcr-Abl-transformed B-cell leukemias were completely eradicated by the alloantigen-specific T cells. "

01/17/2013 - "APG101 did not interfere with the GVT effect, because P815 mastocytoma and most importantly primary Bcr-Abl-transformed B-cell leukemias were completely eradicated by the alloantigen-specific T cells. "

05/01/2012 - "These results support further clinical evaluation of APG101 at a dose of 400 mg per week in glioblastoma patients."
01/01/2018 - "Although CD95 signaling may be relevant for multiple aspects of tumor growth, the mechanism of action of APG101 in glioblastoma is not clear. "
12/15/2021 - "Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in glioblastoma. "
08/01/2015 - "We conclude that CD95L from autocrine and paracrine sources contributes towards the invasive phenotype of glioblastoma cells and that APG101 acts as a suppressor of proinvasive signalling by the CD95/CD95L pathway in glioblastoma. "
01/01/2018 - ": APG101 (asunercept) successfully used in a controlled phase II glioblastoma trial (NCT01071837) acts anti-invasively by inhibiting matrix metalloproteinase signaling, resulting in additive effects together with radiotherapy and helping to further develop a treatment for this devastating disease. "

12/08/2020 - "Asunercept (APG101) is a well-tolerated CD95-ligand inhibitor that showed promising efficacy in a prospective, single-arm phase I study in anemic, transfusion-dependent patients with low and intermediate risk myelodysplastic syndrome (MDS). "
03/22/2016 - "APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis."